Safety reporting on implantation of autologous adipose tissue-derived stem cells with platelet-rich plasma into human articular joints

BMC Musculoskeletal Disorders

Sang Hee Lee¹  Jung Hun Lee¹  Jae-Jin Chang²  Jaewoo Pak³ 

[1] National Leading Research Laboratory, Department of Biological Sciences, Myongji University, 116 Myongjiro, Yongin, Gyeonggido 449-728, Republic of Korea;Oriental Bio Group, Seongnam, Republic of Korea;Stems Medical Clinic, Fourth Floor, 32-3 Chungdam-dong, Gangnam-gu, Seoul 135-950, Republic of Korea

关键词: Orthopedics;    Safety;    Complications;    Platelet-rich plasma;    Adipose tissue-derived stem cells;    Mesenchymal stem cell;   

Others  :  1129120
DOI  :  10.1186/1471-2474-14-337

 received in 2012-12-02, accepted in 2013-11-27,  发布年份 2013

【 摘 要 】

Background

Adipose tissue-derived stem cells (ADSCs), a type of mesenchymal stem cells (MSCs), have great potential as therapeutic agents in regenerative medicine. Numerous animal studies have documented the multipotency of ADSCs, showing their capabilities to differentiate into tissues such as muscle, bone, cartilage, and tendon. However, the safety of autologous ADSC injections into human joints is only beginning to be understood and the data are lacking.

Methods

Between 2009 and 2010, 91 patients were treated with autologous ADSCs with platelet-rich plasma (PRP) for various orthopedic conditions. Stem cells in the form of stromal vascular fraction (SVF) were injected with PRP into various joints (n = 100). All patients were followed for symptom improvement with visual analog score (VAS) at one month and three months. Approximately one third of the patients were followed up with third month magnetic resonance imaging (MRI) of the injected sites. All patients were followed up by telephone questionnaires every six months for up to 30 months.

Results

The mean follow-up time for all patients was 26.62 ± 0.32 months. The follow-up time for patients who were treated in 2009 and early 2010 was close to three years. The relative mean VAS of patients at the end of one month follow-up was 6.55 ± 0.32, and at the end of three months follow-up was 4.43 ± 0.41. Post-procedure MRIs performed on one third of the patients at three months failed to demonstrate any tumor formation at the implant sites. Further, no tumor formation was reported in telephone long-term follow-ups. However, swelling of injected joints was common and was thought to be associated with death of stem cells. Also, tenosinovitis and tendonitis in elderly patients, all of which were either self-limited or were remedied with simple therapeutic measures, were common as well.

Conclusions

Using both MRI tracking and telephone follow ups in 100 joints in 91 patients treated, no neoplastic complications were detected at any ADSC implantation sites. Based on our longitudinal cohort, the autologous and uncultured ADSCs/PRP therapy in the form of SVF could be considered to be safe when used as percutaneous local injections.

【 授权许可】

   
2013 Pak et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Ando W, Tateishi K, Hart DA, Katakai D, Tanaka Y, Nakata K, Hashimoto J, Fujie H, Shino K, Yoshikawa H, Nakamura N: Cartilage repair using an in vitro generated scaffold-free tissue-engineered construct derived from porcine synovial mesenchymal stem cells. Biomaterials 2007, 28:5462-5470.
• [2]Ando W, Tateishi K, Katakai D, Hart DA, Hiquchi C, Nakata K, Hashimoto J, Fujie H, Shino K, Yoshikawa H, Nakamura N: In vitro generation of a scaffold-free tissue-engineered construct (TEC) derived from human synovial mesenchymal stem cells: biological and mechanical properties, and further chondrogenic potential. Tissue Eng Part A 2008, 14:2041-2049.
• [3]Tallheden T, Dennis JE, Lennon DP, Sjoqren-Jansson E, Caplan AI, Lindahl A: Phenotypic plasticity of human articular chondrocytes. J Bone Joint Surg Am 2003, 85-A(Suppl):93-100.
• [4]Nevo Z, Robinson D, Horowitz S, Hasharoni A, Yayon A: The manipulated mesenchymal stem cells in regenerated skeletal tissues. Cell Transplant 1998, 7:63-70.
• [5]Bielby R, Jones E, McGonagle D: The role of mesenchymal stem cells in maintenance and repair of bone. Injury 2007, 38(Suppl):26-32.
• [6]Wakitani S, Goto T, Pineda SJ, Young RG, Mansour JM, Caplan AI, Goldberg VM: Mesenchymal cell-based repair of large, full-thickness defects of articular cartilage. J Bone Joint Surg Am 1994, 76:579-592.
• [7]Sakai D, Mochida J, Yamamoto Y, Nomura T, Okuma M, Nishimura K, Nakai T, Ando K, Hotta T: Transplantation of mesenchymal stem cells embedded in Atelocollagen gel to the intervertebral disc: a potential therapeutic model for disc degeneration. Biomaterials 2003, 24:3531-3541.
• [8]Johnstone B, Yoo JU: Autologous mesenchymal progenitor cells in articular cartilage repair. Clin Orthop Relat Res 1999, 367(Suppl):156-162.
• [9]Agung M, Ochi M, Yanada S, Adachi N, Izuta Y, Yamasaki T, Toda K: Mobilization of bone marrow derived mesenchymal stem cells into the injured tissues after intraarticular injection and their contribution to tissue regeneration. Knee Surg Sports Traumatol Arthrosc 2006, 14:1307-1314.
• [10]Sakai D, Mochida J, Iwashina T, Watanabe T, Nakai T, Ando K, Hotta T: Differentiation of mesenchymal stem cells transplanted to a rabbit degenerative disc model: potential and limitations for stem cell therapy in disc regeneration. Spine 2005, 30:2379-2387.
• [11]Walsh CJ, Goodman D, Caplan AI, Goldberg VM: Meniscus regeneration in a rabbit partial meniscectomy model. Tissue Eng 1999, 5:327-337.
• [12]Nishimori M, Deie M, Kanaya A, Exham H, Adachi N, Ochi M: Repair of chronic osteochondral defects in the rat. A bone marrow-stimulating procedure enhanced by cultured allogenic bone marrow mesenchymal stromal cells. J Bone Joint Surg Br 2006, 88:1236-1244.
• [13]Yamasaki T, Deie M, Shinomiya R, Izuta Y, Yasunaqa Y, Yanada S, Sharman P, Ochi M: Meniscal regeneration using tissue engineering with a scaffold derived from a rat meniscus and mesenchymal stromal cells derived from rat bone marrow. J Biomed Mater Res A 2005, 75:23-30.
• [14]Kanaya A, Deie M, Adachi N, Nishimori M, Yanada S, Ochi M: Intra-articular injection of mesenchymal stromal cells in partially torn anterior cruciate ligaments in a rat model. Arthroscopy 2007, 23:610-617.
• [15]Barry FP: Mesenchymal stem cell therapy in joint disease. Novartis Found Symp 2003, 249:86-96.
• [16]Centeno CJ, Kisiday J, Freeman M, Schultz JR: Partial regeneration of the human hip via autologous bone marrow nucleated cell transfer: a case study. Pain Physician 2006, 9:253-256.
• [17]Centeno CJ, Busse D, Kisiday J, Keohan C, Freeman M, Karli D: Regeneration of meniscus cartilage in a knee treated with percutaneously implanted autologous mesenchymal stem cells. Med Hypotheses 2008, 71:900-908.
• [18]Giannini S, Buda R, Cavallo M, Ruffilli A, Cenacchi A, Cavallo C, Vannini F: Cartilage repair evolution in post-traumatic osteochondral lesions of the talus: from open field autologous chondrocyte to bone-marrow-derived cells transplantation. Injury 2010, 41:1196-1203.
• [19]Pak J: Autologous adipose tissue-derived stem cells induce persistent bone-like tissue in osteonecrotic femoral heads. Pain Physician 2012, 15:75-85.
• [20]Pak J, Lee JH, Lee SH: A novel biological approach to treat chondromalacia patellae. PLoS One 2013, 8:e64569.
• [21]Kulakov AA, Goldshtein DV, Grigoryan AS, Rzhaninova AA, Alekseeva IS, Arutyunyan IV, Volkov AV: Clinical study of the efficiency of combined cell transplant on the basis of multipotent mesenchymal stromal adipose tissue cells in patients with pronounced deficit of the maxillary and mandibulary bone tissue. Bull Exp Biol Med 2008, 146:522-525.
• [22]Mesimäki K, Lindroos B, Törnwall J, Mauno J, Lindqvist C, Kontio R, Miettinen S, Suuronen R: Novel maxillary reconstruction with ectopic bone formationby GMP adipose stem cells. Int J Oral Maxillofac Surg 2009, 38:201-209.
• [23]Taylor JA: Bilateral orbitozygomatic reconstruction with tissue-engineered bone. J Craniofac Surg 2010, 21:1612-1614.
• [24]Kuroda R, Ishida K, Matsumoto T, Akisue T, Fujioka H, Mizuno K, Ohgushi H, Wakitani S, Kurosaka M: Treatment of a full-thickness articular cartilage defect in the femoral condyle of an athlete with autologous bone marrow-stromal cells. Osteoarthr Cartil 2007, 15:226-231.
• [25]Slynarski K, Deszczynski J, Karpinski J: Fresh bone marrow and periosteum transplantation for cartilage defects of the knee. Transplant Proc 2006, 38:318-319.
• [26]Wakitani S, Okabe T, Horibe S, Mitsuoka T, Saito M, Koyama T, Nawata M, Tensho K, Kato H, Uematsu K, Kuroda R, Kurosaka M, Yoshiya S, Hattori K, Ohgushi H: Safety of autologous bone marrow-derived mesenchymal stem cell transplantation for cartilage repair in 41 patients with 45 joints followed for up to 11 years and 5 months. J Tissue Eng Regen Med 2011, 5:146-150.
• [27]Caplan AI: Mesenchymal stem cell. J Orthop Res 1991, 9:641-650.
• [28]Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser JK, Benhaim P, Hedrick MH: Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002, 13:4279-4295.
• [29]Martineau I, Lacoste E, Gagnon G: Effects of calcium and thrombin on growth factor release from platelet concentrates: kinetics and regulation of endothelial cell proliferation. Biomaterials 2004, 25:4489-4502.
• [30]Doucet C, Ernou I, Zhang Y, Llense JR, Begot L, Holy X, Lataillade JJ: Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol 2005, 205:228-236.
• [31]Bernardo ME, Avanzini MA, Perotti C, Cometa AM, Moretta A, Lenta E, Del Fante C, Novara F, de Silvestri A, Amendola G, Zuffardi O, Maccario R, Locatelli F: Optimization of in vitro expansion of human multipotent mesenchymal stromal cells for cell-therapy approaches: further insights in the search for a fetal calf serum substitute. J Cell Physiol 2007, 211:121-130.
• [32]Müller I, Kordowich S, Holzwarth C, Spa-no C, Isensee G, Staiber A, Viebahn S, Gieseke F, Langer H, Gawaz MP, Horwitz EM, Conte P, Handgretinger R, Dominici M: Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM. Cytotherapy 2006, 8:437-444.
• [33]Schallmoser K, Bartmann C, Rohde E, Reinisch A, Kashofer K, Stadelmeyer E, Drexler C, Lanzer G, Linkesch W, Strunk D: Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion 2007, 47:1436-1446.
• [34]Centeno CJ, Schultz JR, Cheever M, Robinson B, Freeman M, Marasco W: Safety and complications reporting on the re-implantation of culture-expanded mesenchymal stem cells using autologous platelet lysate technique. Curr Stem Cell Res Ther 2010, 5:81-93.
• [35]Miura M, Miura Y, Padilla-Nash HM, Molinolo AA, Fu B, Patel V, Seo BM, Sonoyama W, Zheng JJ, Baker CC, Chen W, Ried T, Shi S: Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 2006, 24:1095-1103.
• [36]Bochkov NP, Voronina ES, Kosyakova NV, Liehr T, Rzhaninova AA, Katosova LD, Platonova VI, Gol’dshtein DV: Chromosome variability of human multipotent mesenchymal stromal cells. Bull Exp Biol Med 2007, 143:122-126.
• [37]Izadpanah R, Kaushal D, Kriedt C, Tsien F, Patel B, Dufour J, Bunnell BA: Long-term in vitro expansion alters the biology of adult mesenchymal stem cells. Cancer Res 2008, 68:4229-4238.
• [38]Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A, Montaqna D, Maccario R, Villa R, Daidone MG, Zuffardi O, Locatelli F: Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 2007, 67:9142-9149.
• [39]Vacanti V, Kong E, Suzuki G, Sato K, Canty JM, Lee T: Phenotypic changes of adult porcine mesenchymal stem cells induced by prolonged passaging in culture. J Cell Physiol 2005, 205:194-201.
• [40]Amrani DL, Port S: Cardiovascular disease: potential impact of stem cell therapy. Expert Rev Cardiovasc Ther 2003, 1:453-461.
• [41]Korean Food and Drug Administration: Cell therapy: Rules and Regulations, Chapter 2, Section 14. Seoul (Korea): The Organization; 2009.
• [42]Fan W, Cheng K, Qin X, Narsinh KH, Wang S, Hu S, Wang Y, Chen Y, Wu JC, Xiong L, Cao F: mTORC1 and mTORC2 play different roles in the functional survival of transplanted adipose-derived stromal cells in hindlimb ischemic mice via regulating inflammation in vivo. Stem Cells 2013, 31:203-214.
• [43]Rock KL, Kono H: The inflammatory response to cell death. Annu Rev Pathol 2008, 3:99-126.
• [44]Halperin N, Axer A: The painful semimembranosus syndrome. Harefuah 1978, 94:329-330.
• [45]Almekinders LC, Vellema JH, PS : Strain patterns in the patellar tendon and the implications for patellar tendinopathy. Knee Surg Sports Traumatol Arthrosc 2002, 10:2-5.
• [46]Horie M, Sekiya I, Muneta T, Ichinose S, Matsumoto K, Saito H, Murakami T, Kobayashi E: Intra-articular Injected synovial stem cells differentiate into meniscal cells directly and promote meniscal regeneration without mobilization to distant organs in rat massive meniscal defect. Stem Cells 2009, 27:878-887.